In the present study, GO functional and KEGG enrichment analyses revealed that YXTMD primarily targets the PI3K-Akt signaling pathway, proteoglycan in cancer, Rap1 signaling pathway, MAPK signaling pathway, microRNAs in cancer, and lipids and atherosclerosis in the treatment of CHD with BSS. This evidence concerns the gene AKT1 and atherosclerosis.